Batoclimab (also known as HBM9161 or HL161) is a fully human monoclonal antibody administered by subcutaneous injection. It works by inhibiting the neonatal fragment crystallizable receptor, which leads to a reduction in antibodies of the thyrotropin receptor. It is being developed to treat myasthenia gravis and thyroid eye disease.